MET and cancer: LMS1 was further characterized by several oncogenic signatures in the MAPK and MET signaling pathways (including KRAS and BRAF signatures), as well as cancer aggressiveness (cell migration, hypoxia) and a signature of resistance to the standard chemotherapeutic agent 5-fluorouracil.